Yes, switching from Linzess to Trulance is a reasonable option when Linzess is not effective.
Both Linzess (linaclotide) and Trulance (plecanatide) are guanylate cyclase-C (GC-C) agonists with similar mechanisms of action, and switching between them is supported by current gastroenterology guidelines as a valid treatment strategy when initial therapy fails 1.
Why This Switch Makes Sense
Both medications work through the same mechanism—activating GC-C receptors to increase intestinal fluid secretion and reduce pain signaling. However, individual patient responses can vary significantly despite their mechanistic similarities. The 2023 AGA-ACG guidelines explicitly list both linaclotide and plecanatide as equivalent first-line prescription options for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) 1.
Key evidence supporting this approach:
Similar efficacy profiles: Meta-analyses demonstrate comparable effectiveness between linaclotide and plecanatide for FDA composite endpoints (improvement in both abdominal pain and bowel movements), with no statistically significant differences in treatment response 2, 3
Individual variation in response: Real-world treatment guidelines specifically recommend "retrying past treatment options or combining agents from alternative classes" when initial prescription treatments fail, acknowledging that patient responses differ 4
Different formulations may matter: Despite similar mechanisms, the drugs have different molecular structures and pharmacokinetic properties that could explain variable individual responses
Practical Switching Strategy
Before switching, ensure Linzess was adequately trialed:
- Used for at least 4-12 weeks (diarrhea typically occurs within 2-4 weeks if it's going to happen) 5, 6
- Taken correctly: 30 minutes before first meal of the day on empty stomach 5
- Appropriate dose attempted: For IBS-C, the standard dose is 290 mcg; for CIC, doses range from 72-145 mcg 1
When switching to Trulance:
- Standard dose is 3 mg once daily 1, 6
- Also taken before first meal on empty stomach 6
- Allow 4-12 weeks to assess response
- Monitor for diarrhea, which is the most common side effect (occurs in excess of placebo with both drugs) 7, 2
Important Caveats
The evidence shows similar efficacy and safety between these drugs 2, 3. A 2018 meta-analysis found no statistically significant differences in odds ratios for efficacy, diarrhea, or diarrhea-related withdrawals between linaclotide and plecanatide 2. This means switching may not guarantee better results, but it's worth trying because:
- Individual pharmacologic responses vary
- Some patients respond to one GC-C agonist but not another
- There are no head-to-head trials, so real-world individual variation exists
Safety considerations:
- Both drugs carry similar diarrhea risk (5-8 times higher than placebo) 7, 2
- Plecanatide may have slightly lower overall adverse event rates in some analyses 8
- Both are contraindicated in children under 6 years due to risk of serious dehydration 5, 6
Alternative Considerations
If Trulance also fails, the 2023 guidelines support several next steps 1:
- Prucalopride (5-HT4 agonist, different mechanism)
- Lubiprostone (chloride channel activator, different mechanism)
- Combination therapy with agents from different classes
- Osmotic laxatives (polyethylene glycol) if not already tried adequately
The key is systematic trial of adequate doses for sufficient duration before declaring treatment failure.